92161-14-3

Usage

Yellow crystalline substance

The compound appears as yellow crystals, which is a description of its physical form and color.

Molecular weight

323.14 g/mol The molecular weight of the compound is 323.14 grams per mole, which is the mass of one mole of the compound.

Building block in synthesis

2-(4-nitrobenzyloxy)-5-bromobenzaldehyde is commonly used as a building block in the synthesis of various organic compounds, particularly in the pharmaceutical industry.

Chemical structure

The compound consists of a benzaldehyde group attached to a 5-bromobenzene ring and a 4-nitrobenzyloxy group, which makes it versatile for chemical reactions.

Useful in drug development

Due to its properties, 2-(4-nitrobenzyloxy)-5-bromobenzaldehyde is useful in the development of new drugs.

Applicable in organic synthesis

The compound is also valuable in organic synthesis, as its properties and structure allow for various chemical reactions to be performed.

Upstream product

• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 1761-61-1 5-bromosalicyclaldehyde 
• 100-14-1 4-nitrobenzyl chloride 

Downstream Products

• 28718-76-5 5-bromo-2-(4'-nitrophenyl)benzofuran 

Relevant academic research and scientific papers

INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

CCR5 receptor antagonists: Discovery and SAR study of guanylhydrazone derivatives

High throughput screening (HTS) led to the identification of the guanylhydrazone of 2-(4-chlorobenzyloxy)-5-bromobenzaldehyde as a CCR5 receptor antagonist. Initial modifications of the guanylhydrazone series indicated that substitution of the benzyl group at the para-position was well tolerated. Substitution at the 5-position of the central phenyl ring was critical for potency. Replacement of the guanylhydrazone group led to the discovery of a novel series of CCR5 antagonists.